Document


AGILENT TECHNOLOGIES, INC.
LIFE SCIENCES AND APPLIED MARKETS SEGMENT
(Unaudited)

All periods below were revised to reflect the movement of the chemistries and supplies business and remarketed instruments business from our Agilent CrossLab business segment to our Life Sciences and Applied Markets business segment and the movement of service revenue and cost of sales related to the acquisition of BioTek from our Life Sciences and Applied Markets business segment to our Agilent CrossLab business segment.

(In millions, except margins data)		FY21
		Q1			Q2			Q3			Q4			Total

	Revenue	$	923		$	881		$	897		$	962		$	3,663
	Gross margin %	60.3		%	59.9		%	60.4		%	59.9		%	60.2		%
	Research and development expenses	$	65		$	69		$	67		$	71		$	272
	Selling, general and administrative expenses	$	227		$	233		$	225		$	230		$	915
	Income from operations	$	265		$	226		$	250		$	276		$	1,017
	Operating margin %	28.6		%	25.7		%	27.9		%	28.7		%	27.8		%


		FY20
		Q1			Q2			Q3			Q4			Total

	Revenue	$	816		$	701		$	733		$	865		$	3,115
	Gross margin %	60.4		%	59.0		%	59.7		%	59.2		%	59.6		%
	Research and development expenses	$	62		$	59		$	59		$	64		$	244
	Selling, general and administrative expenses	$	215		$	196		$	192		$	217		$	820
	Income from operations	$	215		$	159		$	187		$	231		$	792
	Operating margin %	26.4		%	22.7		%	25.5		%	26.7		%	25.4		%


		FY19
		Q1			Q2			Q3			Q4			Total

	Revenue	$	785		$	710		$	729		$	803		$	3,027
	Gross margin %	61.5		%	60.3		%	60.5		%	60.6		%	60.7		%
	Research and development expenses	$	63		$	60		$	60		$	61		$	244
	Selling, general and administrative expenses	$	206		$	203		$	203		$	208		$	820
	Income from operations	$	214		$	165		$	178		$	218		$	775
	Operating margin %	27.3		%	23.2		%	24.5		%	27.2		%	25.6		%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, business exit and divestiture costs and special compliance costs.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.


AGILENT TECHNOLOGIES, INC.
DIAGNOSTICS AND GENOMICS SEGMENT
(Unaudited)

No change. Included to show our business segments structure in its entirety.

(In millions, except margins data)		FY21
		Q1			Q2			Q3			Q4			Total

	Revenue	$	294		$	315		$	346		$	341		$	1,296
	Gross margin %	51.6		%	53.4		%	53.5		%	52.5		%	52.8		%
	Research and development expenses	$	29		$	30		$	33		$	36		$	128
	Selling, general and administrative expenses	$	68		$	69		$	74		$	72		$	283
	Income from operations	$	55		$	69		$	78		$	71		$	273
	Operating margin %	18.6		%	21.9		%	22.6		%	20.8		%	21.0		%


		FY20
		Q1			Q2			Q3			Q4			Total

	Revenue	$	249		$	263		$	241		$	294		$	1,047
	Gross margin %	51.7		%	55.1		%	49.8		%	50.9		%	51.9		%
	Research and development expenses	$	32		$	30		$	24		$	28		$	114
	Selling, general and administrative expenses	$	63		$	58		$	55		$	62		$	238
	Income from operations	$	34		$	57		$	41		$	60		$	192
	Operating margin %	13.5		%	21.6		%	17.2		%	20.3		%	18.3		%


		FY19
		Q1			Q2			Q3			Q4			Total

	Revenue	$	235		$	254		$	263		$	269		$	1,021
	Gross margin %	54.0		%	54.8		%	55.7		%	54.0		%	54.7		%
	Research and development expenses	$	31		$	29		$	33		$	32		$	125
	Selling, general and administrative expenses	$	63		$	61		$	64		$	60		$	248
	Income from operations	$	33		$	49		$	50		$	53		$	185
	Operating margin %	14.0		%	19.3		%	19.1		%	19.7		%	18.2		%


AGILENT TECHNOLOGIES, INC.
AGILENT CROSSLAB SEGMENT
(Unaudited)

All periods below were revised to reflect the movement of the chemistries and supplies business and remarketed instruments business from our Agilent CrossLab business segment to our Life Sciences and Applied Markets business segment and the movement of service revenue and cost of sales related to the acquisition of BioTek from our Life Sciences and Applied Markets business segment to our Agilent CrossLab business segment.

(In millions, except margins data)		FY21
		Q1			Q2			Q3			Q4			Total

	Revenue	$	331		$	329		$	343		$	357		$	1,360
	Gross margin %	46.8		%	45.3		%	46.6		%	48.3		%	46.8		%
	Research and development expenses	$	9		$	8		$	9		$	8		$	34
	Selling, general and administrative expenses	$	70		$	72		$	67		$	70		$	279
	Income from operations	$	76		$	69		$	84		$	94		$	323
	Operating margin %	23.1		%	21.0		%	24.4		%	26.3		%	23.8		%


		FY20
		Q1			Q2			Q3			Q4			Total

	Revenue	$	292		$	274		$	287		$	324		$	1,177
	Gross margin %	46.2		%	46.4		%	47.6		%	47.3		%	46.9		%
	Research and development expenses	$	8		$	8		$	8		$	9		$	33
	Selling, general and administrative expenses	$	65		$	58		$	58		$	66		$	247
	Income from operations	$	62		$	61		$	71		$	78		$	272
	Operating margin %	21.1		%	22.3		%	24.7		%	24.2		%	23.1		%


		FY19
		Q1			Q2			Q3			Q4			Total

	Revenue	$	264		$	274		$	282		$	295		$	1,115
	Gross margin %	45.7		%	46.1		%	46.5		%	47.8		%	46.6		%
	Research and development expenses	$	8		$	8		$	7		$	7		$	30
	Selling, general and administrative expenses	$	63		$	61		$	62		$	61		$	247
	Income from operations	$	50		$	57		$	62		$	73		$	242
	Operating margin %	19.0		%	20.9		%	21.8		%	24.6		%	21.7		%